REPLIMUNE GROUP, INC. (REPL)
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Quantum Cyber Approves Acquisition of Equity Stake in SpaceX
Annual Financial Report and Notice of Annual General Meeting
Cineverse Reports Fourth Quarter and Fiscal Year 2026 Results
Abacus Global Management’s Defamation Suit Against Coventry and its Chairman Alan Buerger Advances in U.S. District Court
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
Locafy Reports 31% Revenue Growth for the First Nine Months of Fiscal 2026
Mount Logan Capital Inc. to Join the Russell Microcap® Index
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Upexi Added to the Russell Microcap® Index